ADDITIONAL INFORMATION BOARD AND COMMITTEE ATTENDANCE The table below shows the number of Board and Committee meetings each Director was eligible to attend and attended during the financial year ended 31 December 2025: Board Audit and Risk Remuneration Director Eligible Attended Eligible Attended Eligible Attended Patrick Davies 10 10 2 2 3 3 Dianne Angus 10 10 2 2 3 3 Dr Jenny Harry 10 10 2 2 3 3 Jonathan Pilcher* 10 10 – 2 – 3 Joe Basile 10 9 2 2 3 3 * Jonathan Pilcher attended the Audit and Risk Committee and Remuneration Committee meetings by invitation. INTERESTS REGISTER The Company is required to maintain an interests register in which particulars of certain transactions and matters involving Directors must be recorded. Details of the entries in this register for each of the Directors during and since the end of 2025 are as follows: Director Ordinary Shares Purchased/(Sold) Consideration Paid/(Received) Date of Transaction Joe Basile 14,500 $153,159 16-Apr-25 Jon Pilcher 1,500,000 $2,760,000 22-Jul-25 Jon Pilcher (398,207) ($7,964,140) 8-Sep-25 Joe Basile 12,300 $151,964 5-Mar-26 INFORMATION USED BY DIRECTORS During the year the Board received no notices from Directors of the Company requesting to use Company information received in their capacity as Directors, which would not otherwise have been available to them. INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS Neuren has entered into a deed of indemnity, insurance and access with Directors and Officers, which provides that Directors and Officers generally will incur no monetary loss as a result of actions undertaken by them as Directors and Officers. The indemnity does not cover criminal liability or liability in respect of a breach of a director’s duty to act in good faith and in what the director believes to be the best interests of the Company or a breach of any fiduciary duty owed to the Company or a subsidiary. DONATIONS No donations were made by the Company or its subsidiary companies during the year (2024: $nil). Neuren Pharmaceuticals Limited Annual Report 2025 59
RkJQdWJsaXNoZXIy MjE2NDg3